KKR made the follow-on investment.
The company intends to use the funds for the ongoing market conversion of its Uscan intelligent ultrasound tool for bladder and kidney care, while advancing a nursing tool with a vein-finding solution and bringing a major new Artificial Intelligence (AI)-driven ultrasound project to market.
Led by Kevin Goodwin, CEO, and Niko Pagoulatos, PhD, COO & CIO, EchoNous’ Signostics is applying artificial intelligence, including deep and machine learning, with miniaturization of ultrasound to provide a device, called Uscan, to precisely measure bladder volume and bladder wall thickness. The company has regulatory approvals in the U.S., Australia, Canada, Europe, Singapore and Japan, and exports to countries around the world.
Signostics intends to leverage its AI ultrasound technology to address peripheral IV access in early 2018.